A Phase 3 interventional study of PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and Intravitreal Ranibizumab 0.5 mg Injection in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Active, not recruiting at 89 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2019, is one of 14 in phase 3, and was the 12th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 672 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W).
The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
Inclusion Criteria:
Study eye
Exclusion Criteria:
Substudy:
Inclusion Criteria:
Exclusion Criteria (Cohort 1 Only):
Ocular Exclusion Criteria for Study Eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the PDS arm will receive IVT ranibizumab injection Q4W (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Ranibizumab refill exchange
Participants randomized to the intravitreal arm will receive IVT ranibizumab injection Q4W until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
Drug: Intravitreal Ranibizumab 0.5 mg Injection · Drug: Ranibizumab refill exchange
Participants will undergo re-implantation with the updated PDS implant (pre-filled with ranibizumab 100 milligrams per milliliter \[mg/mL\]) on Day 1 (or enrollment visit) and then will have two refill-exchanges (ranibizumab 100 mg/mL) Q24W up to 48 weeks.
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Ranibizumab refill exchange
Participants who received an updated PDS implant, have \< 24 weeks post-re-implantation follow-up and no scheduled refill-exchange visit in the main study, will undergo two refill-exchange procedures (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.
Drug: Ranibizumab refill exchange
Participants who received an updated PDS implant, have \< 48 weeks post-re-implantation follow-up and one refill exchange visit in the main study, regardless of whether the refill exchange was administered or the visit was missed, will undergo one refill-exchange procedure (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.
Drug: Ranibizumab refill exchange
Will be administered as per the schedule described in individual arm.
Will be administered as per the schedule described in individual arm.
Will be administered as per the schedule described in individual arm.
Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured Using the ETDRS Chart in the Efficacy Population Using a Treatment Policy Strategy for all Intercurrent Events
BCVA = Best-Corrected Visual Acuity ETDRS = Early Treatment Diabetic Retinopathy Study A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
Time frame: Baseline to Week 64
Substudy: Number of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of Ocular and Systemic AEs
Time frame: Baseline to Week 72
Substudy: Number of Participants With Adverse Events of Special Interests (AESIs) and Severity of AESIs
Time frame: Baseline to Week 72
Substudy: Duration of AESIs
Time frame: Baseline to Week 72
Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Post-operative Period
Time frame: Up to Day 37 post re-implantation
Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Follow-up Period
Time frame: > 37 days post-implantation (up to approximately 72 weeks)
Substudy: Duration of Ocular AESIs During the Post-operative Period
Time frame: Up to Day 37 post re-implantation
Substudy: Duration of Ocular AESIs During the Follow-up Period
Time frame: > 37 days post-implantation (up to approximately 72 weeks)
Substudy: Number of Participants With Adverse Device Effects (ADEs) and Severity of ADEs
Time frame: Baseline to Week 72
Substudy: Number of Participants With Anticipated Serious ADEs
Time frame: Baseline to Week 72
Substudy: Duration of Serious ADEs
Time frame: Baseline to Week 72
Substudy: Number of Device Deficiencies
Time frame: Baseline to Week 72
Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured With Use of the ETDRS Chart in the Modified Intent-to-treat (mITT) Population Using a Treatment Policy Strategy for All Intercurrent Events
ETDRS-DRSS = ETDRS Diabetic Retinopathy Severity Scale
Time frame: Baseline to Week 64
Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured With Use of the ETDRS Chart in the mITT Population Using a Hypothetical Strategy for All Intercurrent Events
Time frame: Baseline to Week 64
Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS at Week 64 in the Efficacy Population
Time frame: Baseline to Week 64
Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS at Week 64 in the mITT population
Time frame: Baseline to Week 64
Change from Baseline in BCVA as Measured on the ETDRS Chart Over Time
Time frame: Baseline up to Week 120
Percentage of Participants Who Lose <15, <10, and <5 letters in BCVA From Baseline Over Time
Time frame: Baseline up to Week 120
Percentage of Participants Who Gain ≥15, ≥10, ≥5, ≥0 Letters in BCVA From Baseline Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With a BCVA Snellen Equivalent of 20/40 or Better Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With a BCVA Snellen Equivalent of 20/200 or Worse Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With a ≥3-step Improvement From Baseline on the ETDRS-DRSS Over Time
Time frame: Baseline up to Week 120
Time to ≥2-step Worsening From Baseline on the ETDRS-DRSS
Time frame: Baseline up to Week 120
Time to ≥3-step Worsening From Baseline on the ETDRS-DRSS
Time frame: Baseline up to Week 120
Change From Baseline in ETDRS-DRSS Score Over Time
Time frame: Baseline up to Week 120
Change From Baseline in Central Subfield Thickness (CST) as Measured on Spectral Domain Optical Coherence Tomography (SD-OCT) Over Time
Time frame: Baseline up to Week 120
Change From Baseline in Total Macular Volume as Measured on SD-OCT Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time (IRF as Measured in the Central 1 mm Subfield)
Time frame: Baseline up to Week 120
Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time (SRF as Measured in the Central 1 mm Subfield)
Time frame: Baseline up to Week 120
Percentage of Participants With Absence of IRF and SRF Over Time
Time frame: Baseline up to Week 120
Percentage of Participants With Absence DME (Defined as CST ≥325 μm on SD-OCT) Over Time
DME = diabetic macular edema
Time frame: Baseline up to Week 120
Time to PDR (Defined as a Score ≥60 on the ETDRS-DRSS)
PDR = proliferative diabetic retinopathy
Time frame: Baseline up to Week 120
Percentage of Participants Who do not Undergo Supplemental Treatment With IVT Ranibizumab Within Each Refill-exchange Interval
Time frame: Baseline up to Week 120
Percentage of Participants Who Report Preferring PDS Treatment Compared With IVT Ranibizumab Treatment
As measured by the PDS patient preference questionnaire (PPPQ) at Week 64 among participants in the PDS arm efficacy population, mITT population
Time frame: Baseline to Week 64
Percentage of Participants Who Report Preferring PDS Treatment Compared With IVT Ranibizumab Treatment, as Measured by the PPPQ at Week 64
Participants in a subset of patients with bilateral disease who are simultaneously receiving ranibizumab via study eye PDS implant and fellow eye IVT injection.
Time frame: Baseline to Week 64
Participant-reported Vision-related Functioning and Health-Related Quality of Life (HRQoL) Among Participants in Both Treatment Arms, as Measured by Changes From Baseline
As measured by in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite score and Near Activities, Distance Activities, and Driving subscale scores
Time frame: , Baseline Week 48, Week 96
Participant-reported Vision-related Functioning and HRQoL, as Measured by the Proportion of Participants With a ≥ 4-Point Improvement From Baseline in the NEI VFQ-25 Composite Score at Weeks 48 and 96 Among Participants in Both Treatment Arms
Time frame: Baseline, Week 48, Week 96
Incidence and Severity of Ocular AEs
Time frame: Baseline to Week 120
Incidence and Severity of Non-ocular AEs
Time frame: Baseline up to Week 120
Incidence, Severity, and Duration of AEs of Special Interest
Time frame: Baseline up to Week 120
Serum Concentration of Ranibizumab Observed Over Time
Time frame: Baseline up to Week 120
PK Parameter: Value Area Under the Concentration- Time Curve Over 24 weeks (AUC24W)
Time frame: Baseline to Week 24
PK Parameter: Maximum Serum Concentration (Cmax)
Time frame: Baseline up to Week 120
PK Parameter: Minimum Serum Concentration (Cmin)
Time frame: Baseline up to Week 120
Time of Maximum Observed Serum Concentration (Tmax) After PDS Implant Insertion
Time frame: Baseline up to Week 120
Prevalence of Anti-drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study
Time frame: Baseline up to Week 120
Prevalence of Neutralizing Antibodies at Baseline and Incidence of Neutralizing Antibodies During the Study
Time frame: Baseline up to Week 120
Reported Incidence of Device Deficiencies
Time frame: Baseline up to Week 120
Incidence and Severity of Ocular AEs
Time frame: Baseline up to Week 120
Incidence, Severity, and Duration of AESIs
Time frame: Baseline up to Week 120
Incidence, Severity, and Duration of Ocular AESIs During the Postoperative Period (up to 37 Days After Initial Implantation) and Follow-up Period (> 37 days After Implantation Surgery)
Time frame: Baseline up to Week 120
Incidence and Severity of ADEs
Time frame: Baseline up to Week 120
Incidence, Causality, Severity, and Duration of Anticipated Serious ADEs
Time frame: Baseline up to Week 120
Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Substudy: Duration of AESIs After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Substudy: Number of Participants With ADEs and Severity of ADEs After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Substudy: Number of Participants With Anticipated Serious ADEs After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Substudy: Duration of Serious ADEs After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Substudy: Number of Device Deficiencies After Refill-exchange Procedure
Time frame: Up to approximately 72 weeks
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Sep 2019 (actual). Primary completion is estimated for Jul 2027, 93 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 93 months is above that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.